At Stem Cells USA, Shire Regenerative Medicine says it Creates Solutions, Not Therapies

In 2011, Advanced BioHealing whose lead product was Dermagraft, was acquired by Shire to form Shire Regenerative Medicine (SRM). SRM also recently acquired Pervasis, whose product Vascugel enters phase 2 clinical trials next year. These two current technologies direct the focus on treating diabetes complications and dermal repair. At Stem Cells USA, SRM discussed how it is  looking to create medical solutions, which provide a significant value to the healthcare system and to society.

-Original content provided by an on-site blogger at the Stem Cells USA & Regenerative Medicine Congress